BIMI - BOQI International Medical Inc.
M&A a Wall Street: Broadcom acquista VMware per 61 miliardi di dollari
Broadcom acquista VMware in una transazione in contanti e azioni per il valore di 61 miliardi di dollari. L’accordo rappresenta una delle pi grandi acquisizioni tecnologiche di tutti i tempi, …
S&P 500 e lo spauracchio Bear Market: analisi dei precedenti mercati ribassisti e le strategie per affrontare al meglio l’Orso
La settimana scorsa si conclusa con uno S&P 500 sull?orlo di un mercato orso, mentre l?indice Nasdaq Composite entrato in territorio ribassista gi lo scorso marzo. I timori …
Intesa Sanpaolo e Unicredit tra i 5 titoli bancari UE indicati da IG come potenziali winner sui mercati in questo 2022 sfidante
L’ultimissima conferma arrivata proprio oggi, con ilPILUsache calato oltre le attese dell’1,5%. Un segnale chiaro, l’ennesimo, sul rallentamento dell’economia globale scatenato dalla sfortunata combinazione di eventi tra la …
Tutti gli articoli
Tutti gli articoli Tutte le notizie

  1. #1
    L'avatar di BigNick
    Data Registrazione
    Jul 2001
    Messaggi
    7,826
    Mentioned
    10 Post(s)
    Quoted
    1694 Post(s)
    Potenza rep
    42949693

    BIMI - BOQI International Medical Inc.

    Aveva fatto il botto il 19 Ottobre con la trimestrale:
    BOQI International Medical Inc. Announces Second Quarter 2020 Financial Results, Revenue increased by 1026% Over the Same Period Last Year
    BOQI International Medical Inc. Announces Second Quarter 2020 Financial Results, Revenue increased by 1026% Over the Same Period Last Year

    Chi mi aiuta a studiarla ?

    BIMI - BOQI International Medical Inc.-bimi.jpg

  2. #2
    L'avatar di the volture
    Data Registrazione
    Mar 2005
    Messaggi
    7,441
    Mentioned
    1 Post(s)
    Quoted
    341 Post(s)
    Potenza rep
    42949690
    Graficamente fa schifo, sempre in discesa dal massimo di 25$....anche la salita da uno a 25$ e'stata piena di spike...
    Lo tradata recentemente in un rimbalzo iniziato in area 1.9....

    L'unico segnale decente e' la rottura di sma 100 daily o il ritest di 1.5$ o il ritorno a 1$

  3. #3
    L'avatar di BigNick
    Data Registrazione
    Jul 2001
    Messaggi
    7,826
    Mentioned
    10 Post(s)
    Quoted
    1694 Post(s)
    Potenza rep
    42949693
    Citazione Originariamente Scritto da the volture Visualizza Messaggio
    Graficamente fa schifo, sempre in discesa dal massimo di 25$....anche la salita da uno a 25$ e'stata piena di spike...
    Lo tradata recentemente in un rimbalzo iniziato in area 1.9....

    L'unico segnale decente e' la rottura di sma 100 daily o il ritest di 1.5$ o il ritorno a 1$
    a me non sembra cos male, oscillatori scarichi e MACD prossimo all'incrocio, i prossimi giorni potrebbe anche invertire, vediamo...

  4. #4
    L'avatar di BigNick
    Data Registrazione
    Jul 2001
    Messaggi
    7,826
    Mentioned
    10 Post(s)
    Quoted
    1694 Post(s)
    Potenza rep
    42949693
    BOQI International Medical Inc. Announces Third Quarter 2020 Financial Results Nasdaq:BIMI.

    BOQI International Medical Inc. Announces Third Quarter 2020 Financial Results
    Email Print Friendly Share
    November 16, 2020 08:30 ET | Source: BOQI International Medical, Inc.
    NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- BOQI International Medical Inc. (NASDAQ: BIMI) (BIMI or the Company) today announced its financial results for the third quarter and nine months ended September 30, 2020.

    We have made good progress in line with our new business, especially the online-to-offline strategy. We opened our first retail pharmacy store in Chongqing at the end of June 2020, then gradually opened five more stores in the latter part of the third quarter, said Mr. Tiewei Song, Chief Executive Officer and President of BOQI International Medical Inc. We are also developing our online healthcare platform. We plan to connect the platform with pharmacies, hospitals and other medical institutions to further strengthen our capabilities in online and offline healthcare services.

    Revenues

    Revenues for the three months ended September 30, 2020 and 2019 were $3,091,071 and $208,402, respectively. The Companys revenues for the three months ended September 30, 2020 were principally attributable to wholesale sales of medical devices and generic drugs by our newly acquired Guanzan Group. The Companys revenues for the three months ended September 30, 2019 were attributable to the sales of products manufactured by the NF Group and from energy saving technical services and product collaboration processing services performed by the NF Group, which we sold in June 2020. Revenues from the wholesale medical devices segment and the wholesale medicine segment for the three months ended September 30, 2020 were $670,296 and $2,391,674, respectively. Revenues from the retail pharmacy segment for the three months ended September 30, 2020 were $29,101.

    Revenues for the nine months ended September 30, 2020 and 2019 were $7,317,449 and $1,120,804, respectively. The 553% increase in revenues is attributable to the acquisition of the Guanzan Group in late March 2020. Revenues from the wholesale medicine segment for the nine months ended September 30, 2020 were $4,698,985 and revenues from the wholesale medical device segment for the nine months ended September 30, 2020 were $2,567,029. Revenues from the retail pharmacy segment for the nine months ended September 30, 2020 were $42,898.

    Cost of Revenues

    Cost of revenues for the three months ended September 30, 2020 and 2019 were $2,833,793 and $281,014, respectively, reflecting the impact of the acquisition of the Guanzan Group. For the three months ended September 30, 2020, the cost of revenues of the wholesale medical devices segment was $586,939. For the three months ended September 30, 2020, the cost of revenues of our wholesale medicine segment was $2,032,947. For the three months ended September 30, 2020, the cost of revenues for retail pharmacy segment was $227,883, which included an inventory impairment charge of $202,981.

    Cost of revenues for the nine months ended September 30, 2020 and 2019 were $6,240,962 and $1,030,862, respectively. For the nine months ended June 30, 2020, the cost of revenues of our wholesale medical devices segment was $2,051,563. For the nine months ended September 30, 2020, the cost of revenues of our wholesale medicine segment was $3,759,707. For the nine months ended September 30, 2020, cost of revenues of our retail pharmacy segment was $426,293, which included an inventory write-off of $390,923.

    Gross Profit

    For the three months ended September 30, 2020, the Company had a gross profit margin of 8.32% compared with a negative gross profit margin of 34.84 % in the quarter ended September 30, 2019. On a sequential basis, gross profit decreased by 14.07% from the second quarter of 2020, due to the decrease in revenues from high gross profit wholesale medical devices segment. The gross profit margin of the wholesale medical devices and wholesale medicine segments for three months ended September 30, 2020 were 12.44% and 15%, respectively. The retail pharmacy segments cost of revenues exceeded its revenues by $198,782 in the quarter.

    For the nine months ended September 30, 2020, the Company had a gross profit margin of 14.71% compared with a gross profit margin of 8.02% in the first nine months of 2019. The improvement in the gross profit margin in the first nine months ended September 30, 2020 is mainly due to the inclusion of the revenues from the wholesale medical devices and wholesale medicine segments since the acquisition in March 2020. The gross profit margin of the wholesale medical devices and wholesale medicine segments for nine months ended September 30, 2020 were 20.08% and 19.99%, respectively. The retail pharmacy segments cost of revenues exceeded its revenues by $383,395 in the nine-month period ended September 30, 2020.

    Operating Expenses

    Operating expenses were $1,689,962 for the three months ended September 30, 2020 compared to $359,307 for the same period in 2019, an increase of $1,330,655. The increase is mainly due to the additional amortization of the discounted convertible notes and intangible assets and impairment loss of intangible asset.

    Operating expenses were $6,579,201 for the nine months ended September 30, 2020 compared to $1,607,763 for the same period in 2019, an increase of $ 4,975,922 or 309%. Operating expenses for the nine months ended September 30, 2020 consist mainly of amortization of the discounted convertible notes, amortization of intangible assets, meeting and promotional expenses, pharmaceutical and medical device industry compliance management expenses, legal fees, convertible note issuance-related costs in the amount of $211,425 and other professional service fees. The Company also reduced the contingent consideration payable to the former shareholders of Lasting (the parent of Boqi Zhengji) by $5,655,709, following a re-evaluation of such commitment.

    Operating expenses also included a $903,573 impairment loss with respect to the intangible assets recognized in the acquisition of Boqi Zhengji.

    Other Income

    For the three months ended September 30, 2020, the Company reported other income of $5,247 and other interest expense of $339,780, as compared to other income of $58,718 and other interest expense of $ 466,582 for the three months ended September 30, 2019.

    For the nine months ended September 30, 2020, the Company reported other income of $6,973,409 and other interest expense of $717,226 compared to other income of $11,021 and other interest expense of $717,226 in the nine months ended September 30, 2019. Other income in the nine months ended September 30, 2020 includes the gain generated from the disposal of the NF Group.

    Net Profit (Loss)

    For the three months ended September 30, 2020, the Company reported a net loss of $1,860,573 compared to a net loss of $547,689 for the same period of 2019. For the nine months ended September 30, 2020, the Company reported a net profit of $611,090 compared to a net loss of $1,973,382 for the same period in 2019.

    Liquidity and Capital Resources

    On September 30, 2020, the Company had cash and cash equivalents of $11, 585,325 compared to cash and cash equivalents of $36,363 on December 31, 2019. As of September 30, 2020, the Company had negative working capital of $5,439,912 as compared to negative working capital of $500,765 on December 31, 2019.

    These conditions raise substantial doubt about the Companys ability to continue as a going concern. These unaudited condensed financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of these uncertainties. Management believes that the actions presently being taken to obtain additional funding and implement its strategic plan provides the opportunity for the Company to continue as a going concern.

  5. #5
    L'avatar di BigNick
    Data Registrazione
    Jul 2001
    Messaggi
    7,826
    Mentioned
    10 Post(s)
    Quoted
    1694 Post(s)
    Potenza rep
    42949693
    BIMI - BOQI International Medical Inc.-bimi.jpg

    oggi si muove anche questa, massimi a breve, MACD in incrocio positivo, vediamo se mantiene in chiusura

  6. #6
    L'avatar di blackjack1975
    Data Registrazione
    Aug 2006
    Messaggi
    833
    Mentioned
    0 Post(s)
    Quoted
    155 Post(s)
    Potenza rep
    11404205
    Citazione Originariamente Scritto da BigNick Visualizza Messaggio
    BIMI - BOQI International Medical Inc.-bimi.jpg

    oggi si muove anche questa, massimi a breve, MACD in incrocio positivo, vediamo se mantiene in chiusura
    CIAO Nick sopra a che prezzo diventa UP?

  7. #7
    L'avatar di BigNick
    Data Registrazione
    Jul 2001
    Messaggi
    7,826
    Mentioned
    10 Post(s)
    Quoted
    1694 Post(s)
    Potenza rep
    42949693
    Citazione Originariamente Scritto da blackjack1975 Visualizza Messaggio
    CIAO Nick sopra a che prezzo diventa UP?
    come puoi vedere dal grafico in area 1,90/1,93 c' una forte resistenza che anche oggi sembra respingere le quotazioni, per adesso non ci sono volumi, per cui la vedo difficile

  8. #8
    L'avatar di blackjack1975
    Data Registrazione
    Aug 2006
    Messaggi
    833
    Mentioned
    0 Post(s)
    Quoted
    155 Post(s)
    Potenza rep
    11404205
    Citazione Originariamente Scritto da BigNick Visualizza Messaggio
    come puoi vedere dal grafico in area 1,90/1,93 c' una forte resistenza che anche oggi sembra respingere le quotazioni, per adesso non ci sono volumi, per cui la vedo difficile
    ok grazie...

  9. #9
    L'avatar di BigNick
    Data Registrazione
    Jul 2001
    Messaggi
    7,826
    Mentioned
    10 Post(s)
    Quoted
    1694 Post(s)
    Potenza rep
    42949693
    BIMI - BOQI International Medical Inc.-bimi.jpg

    se confermasse in chiusura la candela, direi che potrebbe essere un bel segnale, visto anche l'incrocio di MACD

  10. #10
    L'avatar di blackjack1975
    Data Registrazione
    Aug 2006
    Messaggi
    833
    Mentioned
    0 Post(s)
    Quoted
    155 Post(s)
    Potenza rep
    11404205
    Citazione Originariamente Scritto da bignick Visualizza Messaggio
    BIMI - BOQI International Medical Inc.-bimi.jpg

    se confermasse in chiusura la candela, direi che potrebbe essere un bel segnale, visto anche l'incrocio di macd
    sisi big..grazieeee

Accedi